MAPK3 and hepatocellular carcinoma: Overexpression of SNX5 was documented to inhibit intracellular degradation of EGFR, while in hepatocellular carcinoma (HCC), SNX5 was witnessed to activate the EGFR-ERK1/2 pathway by lowering the circulation rate of EGFR in the endosomal network which leads to an increased amount of EGFR8,9.